Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882129 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL20210401 | 0.86 | — | — | |
| SCHEMBL1234579 | 0.80 | — | — | |
| SCHEMBL13859665 | 0.79 | — | — | |
| SCHEMBL10334120 | 0.76 | — | — | |
| SCHEMBL20165765 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL338407 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14615253 | 0.75 | — | — | |
| SCHEMBL4023703 | 0.73 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL79029 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| CN-119161338-B | Tetrahydropyridine derivatives useful as muscarinic receptor agonists and their pharmaceutical use | 嘉兴安帝康生物科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250110101-A1 | PER AND POLYFLUOROALKYL SUBSTANCE MEASUREMENT | DEXSIL CORPORATION (US) | 2025-04-03 | — | — | US | disclosed |
| US-20240059860-A1 | METHODS AND SYSTEMS FOR DESTRUCTION OF SYNTHETIC PER- AND POLYFLUORO COMPOUNDS | CHZ TECHNOLOGIES, LLC | 2024-02-22 | — | — | US | disclosed |
| CN-115536995-B | PET film for photovoltaic backboard and preparation method thereof | 苏州易昇光学材料股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-10838301-B2 | Resist composition, method of forming resist pattern, fluorine-containing compound, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-2170058-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8445480-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8318656-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| EP-1303258-B1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005074593-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074639-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074594-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074637-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| EP-0943606-A1 | BENZENESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10838301-B2 | Resist composition, method of forming resist pattern, fluorine-containing compound, and compound | AFF1, RER1, AFF2 | SMN1; SMN2 469/4885LMNA 1288/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.